AI
Thursday, March 13, 2025 10:59:30 PM
This appears to be an international patent application, and not a granted patent.
I have not read much more than the first page, but I did notice Figure 1, which a graphical form of the illustration Anavex has been displaying of the parts of the brain that are more or less impacted by blarcamesine during the 48 week 2b/3 trial. (These are the results with the extremely low p value result.)
Please excuse my clumsy editing, but take a look -- the results are pretty astonishing in this format. Keep in mind these are AD patients; a normally aging population will still average about a one percent loss during the 48 week time period.
I have not read much more than the first page, but I did notice Figure 1, which a graphical form of the illustration Anavex has been displaying of the parts of the brain that are more or less impacted by blarcamesine during the 48 week 2b/3 trial. (These are the results with the extremely low p value result.)
Please excuse my clumsy editing, but take a look -- the results are pretty astonishing in this format. Keep in mind these are AD patients; a normally aging population will still average about a one percent loss during the 48 week time period.
